Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Praveen Suchdev

Pain Medicine Nashua, NH Medical Doctor

NPI 1023049814 CMS profile 904561

280 Main St, Ste 330, Nashua, NH 03060

Open in the dashboard

General payments

$72,261

312 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Praveen Suchdev of Nashua, NH is reported in the CMS Open Payments database as having received $72,261 across 312 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $10,305 49
2024 General $12,350 45
2023 General $11,532 47
2022 General $17,220 71
2021 General $12,327 48
2020 General $4,818 21
2019 General $3,709 31

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Praveen Suchdev
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Praveen Suchdev were reported at $10,305. Among 2,779 Pain Medicine profiles paid that year, the median was $458 and the middle half received between $124 and $1,401.

Show as a table
Year Praveen Suchdev Pain Medicine median Middle half National median
2019 $3,709 $498 $126–$1,682 $163
2020 $4,818 $284 $80–$910 $114
2021 $12,327 $399 $112–$1,219 $132
2022 $17,220 $455 $137–$1,484 $149
2023 $11,532 $484 $128–$1,495 $160
2024 $12,350 $498 $131–$1,540 $164
2025 $10,305 $458 $124–$1,401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $64,566 238 payments
  2. Spinal Simplicity, LLC $2,934 15 payments
  3. Vertiflex, Inc. $1,073 7 payments
  4. Abbott Laboratories $894 9 payments
  5. Pacira Pharmaceuticals Incorporated $828 6 payments
  6. Painteq LLC $404 5 payments
  7. SI-BONE, Inc. $360 4 payments
  8. SPR Therapeutics, Inc $258 3 payments
  9. Neuronetics, Inc. $237 2 payments
  10. Curonix LLC $153 2 payments
  11. Other $555 21 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $50,338 36 payments
  2. Food and Beverage $13,039 236 payments
  3. Travel and Lodging $8,884 40 payments
Products named General payments · program years 2019–2025
  1. WaveWriter Alpha Prime 16 $23,423 64 payments
  2. WAVEWRITER ALPHA $9,048 22 payments
  3. GENERAL - PAIN MANAGEMENT Pain Management $4,430 13 payments
  4. HA MINUTEMAN G3-R $2,934 15 payments
  5. SPECTRA WAVEWRITER $2,406 11 payments
  6. General - Pain Management General Pain Management $2,324 9 payments
  7. General - Pain Management General - Pain Management_NMD $1,637 26 payments
  8. Superion ISS $1,073 7 payments
  9. Iovera $828 6 payments
  10. General - Therapies $599 4 payments
  11. Other $4,655 95 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$60,575

Of which drugs: $28

Medicare patients

266

Average age 75

Services billed

1,014

166 women, 100 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 32%
Diabetes 30%
Chronic kidney disease 24%
Osteoporosis 23%
Ischemic heart disease 22%
COPD 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 33 310 $26

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BELBUCA
  • Collegium Pharmaceutical, Inc. $18
$18 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

312 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record